Clinical trials: Cytarabine, completed
Leukemia
Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01228331
- Testing
- Amsacrine, Clofarabine, Cyclophosphamide
- Where
- 14 sites in Germany
- Volunteers
- 745 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Leukemia
Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- AIEOP LLA 2000 (NCT00613457)
- Testing
- dexamethasone, asparaginase, cyclophosphamide
- Volunteers
- 2,039 people
- Sponsor
- Associazione Italiana Ematologia Oncologia Pediatrica
Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL
The investigators postulate that Pevonedistat will be effective in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) when combined with a standard backbone ALL chemotherapy regimen.
- Trial name
- NCT03349281
- Testing
- Pevonedistat, Vincristine, Dexamethasone
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Julio Barredo, MD
Lymphoma
Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00006695
- Testing
- carmustine, cytarabine, etoposide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Nebraska
Leukemia, Myelodysplastic Syndromes
Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Zosuquidar trihydrochloride, a modulator of multidrug resistance (MDR), may help daunorubicin and cytarabine…
- Trial name
- NCT00046930
- Testing
- filgrastim, sargramostim, cytarabine
- Where
- 92 sites in United States, Israel
- Volunteers
- 449 people
- Sponsor
- Eastern Cooperative Oncology Group
Solid Tumour Neoplastic Meningitis, Brain Metastases
Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.
The purpose of this study is to demonstrate the safety of giving Whole Brain Radiotherapy (WBRT) together with intrathecal liposomal cytarabine (DepoCyte®) for patients with leptomeningeal metastases.
- Trial name
- NCT00854867
- Testing
- Whole Brain Radio Therapy (WBRT) with sequential Depocyte, Whole brain radiotherapy (WBRT) with concomitant Depocyte
- Where
- 7 sites in Austria, Germany
- Volunteers
- 18 people
- Sponsor
- Mundipharma Research Limited
Leukemia
2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
Primary Objectives: 1. To determine the response rate, progression-free survival (PFS) and overall survival of patients who receive 2-CdA + Ara-C. 2.
- Trial name
- NCT00483067
- Testing
- 2-CdA, Ara-C, G-CSF (Granulocyte colony-stimulating factor)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myelocytic, Acute
Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)
The AML-03 regimen investigates the addition of G-CSF priming to both induction and consolidation chemotherapies administrated in the previous AML-99 trial (NCT01716793) refines risk-stratification based on biological…
- Trial name
- NCT01723657
- Testing
- Ara-C, Autologous peripheral blood stem cell transplantation., Allogeneic matched related or unrelated donor transplant.
- Where
- 21 sites in Spain
- Volunteers
- 862 people
- Sponsor
- Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Granulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma
This pilot phase I trial studies how well CPI-613 (6,8-bis[benzylthio]octanoic acid), cytarabine, and mitoxantrone hydrochloride work in treating patients with acute myeloid leukemia or granulocytic sarcoma (a malignant…
- Trial name
- NCT02484391
- Testing
- 6,8-Bis(benzylthio)octanoic Acid, Cytarabine, Hematopoietic Cell Transplantation
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Wake Forest University Health Sciences
Hematologic Malignancies, AML
A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies
Patients with refractory or relapsed hematologic malignancies will receive CP-4055 intravenously(IV) on Day 1-5 every three weeks until complete response or disease worsening/progressing
- Trial name
- NCT00405743
- Testing
- CP-4055
- Where
- 16 sites in United States, France and 4 more
- Volunteers
- 153 people
- Sponsor
- Clavis Pharma
Lymphoma
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00005601
- Testing
- rituximab, cisplatin, cytarabine
- Where
- 21 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Leukemia, Myelodysplastic Syndromes
Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Neutropenia
- Trial name
- NCT00002800
- Testing
- filgrastim, lintuzumab, cytarabine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia
Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)
Several groups, especially the PETHEMA group (in their LPA96 and 99 trials), obtained low relapse rates in newly diagnosed Acute Promyelocytic Leukemia (APL) patients by combining ll-transretinoic acid (ATRA) and anthracyclines…
- Trial name
- Ara-C (NCT01191541)
- Testing
- DNR:, Ara-c
- Where
- 2 sites in China
- Volunteers
- 65 people
- Sponsor
- Xiaofan Zhu
Acute Myeloid Leukemia
Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years
In this study safety and tolerability of two dose levels of SU 11248 (sutent) with standard chemotherapy in patients with FLT3 mutated AML over 60 years will be evaluated.
- Trial name
- NCT00783653
- Testing
- Sunitinib
- Where
- 5 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Breast Cancer, Leptomeningeal Metastases
Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer
The purpose of this study is to evaluate the impact of Depocyte® IT combined with the systemic standard treatment in terms of clinical and/or radiological neuromeningeal progression free survival (SSPN)
- Trial name
- DEPOSEIN (NCT01645839)
- Testing
- Liposomal Cytarabine
- Where
- 10 sites in France
- Volunteers
- 74 people
- Sponsor
- Centre Oscar Lambret
Acute Myeloid Leukemia
Study of Dendrogenin A / Oxysterols Balance Between Healthy Volunteers and Acute Myeloid Leukemia Patients
Dendrogenin A is present in mammals normal tissues and fluids, notably blood. It is down-represented or absent in cancer cell lines and tumors.
- Trial name
- OXYLAM (NCT02602587)
- Testing
- Blood sample, Bone marrow sample
- Where
- France
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Lymphoma
Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003311
- Testing
- filgrastim, cyclophosphamide, cytarabine
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myelodysplastic Syndrome
Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies
The purpose of this study is to find a safe dose of actinium-225 when it is labeled to HuM195. This will be done with a "phase I trial," in which a preset schedule of doses gets more powerful for each new group of patients as the…
- Trial name
- NCT00672165
- Testing
- ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase I/II trial studies the side effects and best dose of quizartinib when given in combination with azacitidine or cytarabine in treating patients with acute myeloid leukemia or myelodysplastic syndrome that have come back…
- Conditions
- FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia
- Trial name
- NCT01892371
- Testing
- Azacitidine, Cytarabine, Quizartinib
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant
FLAT-Auto is a phase II trial. fludarabine and ARA-C will be combined with the alkylating agent treosulfan (FLAT), to investigate the feasibility and the efficacy of a new regimen, supported with autologous peripheral blood SCT…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Transplant-Related Hematologic Malignancy
- Trial name
- FLAT-Auto (NCT03961919)
- Testing
- Fludarabine, ARA-C, Treosulfan
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Ciceri Fabio